Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barré syndrome

Journal of Neuroimmunology

Volumn 161, Issue 1-2, 2005, Pages 183-189

  Geleijns, Karin ^a   Laman, Jon D ^a   Van Rijs, Wouter ^a   Tio Gillen, Anne P ^a   Hintzen, Rogier Q ^a   Van Doorn, Pieter A ^a   Jacobs, Bart C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Autoimmunity; B cell; Immune mediated polyneuropathy; Single nucleotide polymorphism; Tumor necrosis factor receptor family

Indexed keywords

FAS ANTIGEN; FAS LIGAND; GANGLIOSIDE ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYNEUROPATHY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONTENT; PROTEIN PROTEIN INTERACTION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 14844314137     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2004.12.001     Document Type: Article

References (31)

1. O. Aktas, S. Waiczies, U. Grieger, U. Wendling, R. Zschenderlein, and F. Zipp Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis J. Neuroimmunol. 114 2001 160 167
2. M.H. Al-Maini, J.D. Mountz, H.A. Al-Mohri, E.M. El-Ageb, B.M. Al-Riyami, K.L. Svenson, T. Zhou, and E.R. Richens Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus Lupus 9 2000 132 139
3. C.W. Ang, B.C. Jacobs, and J.D. Laman Guillain-Barré syndrome, a true case of molecular mimicry Trends Immunol. 25 2004 61 66
4. A.K. Asbury, and D.R. Cornblath Assessment of current diagnostic criteria for Guillain-Barré syndrome Ann. Neurol. 27 1990 S21 S24
5. M. Bilinska, I. Frydecka, R. Podemski, and E. Gruszka Serum levels of sTNFR-1 and sFas in patients with relapsing-remitting multiple sclerosis Med. Sci. Monit. 8 2002 CR720 CR723
6. A.I. Bolstad, A. Wargelius, B. Nakken, H.J. Haga, and R. Jonsson Fas and Fas ligand gene polymorphisms in primary Sjögren's syndrome J. Rheumatol. 27 2000 2397 2405
7. J. Cheng, T. Zhou, C. Liu, J.P. Shapiro, M.J. Brauer, M.C. Kiefer, P.J. Barr, and J.D. Mountz Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule Science 263 1994 1759 1762
8. Dutch Guillain-Barré Study Group Treatment of Guillain- Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study Ann. Neurol. 35 1994 749 752
9. K. Geleijns, B.C. Jacobs, W. Van Rijs, A.P. Tio-Gillen, J.D. Laman, and P.A. van Doorn Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients J. Neuroimmunol. 150 2004 132 138
10. L. Guzman-Rojas, J.C. Sims-Mourtada, R. Rangel, and H. Martinez-Valdez Life and death within germinal centres: a double-edged sword Immunology 107 2002 167 175
11. K. Hamzaoui, A. Hamzaoui, L. Zakraoui, and A. Chabbou Levels of soluble Fas/APO-1 in patients with Behcet's disease Mediat. Inflamm. 7 1998 111 114
12. Q.R. Huang, D. Morris, and N. Manolios Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene Mol. Immunol. 34 1997 577 582
13. S. Kanemitsu, K. Ihara, A. Saifddin, T. Otsuka, T. Takeuchi, J. Nagayama, M. Kuwano, and T. Hara A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus J. Rheumatol. 29 2002 1183 1188
14. B.C. Kieseier, R. Kiefer, R. Gold, B. Hemmer, H.J. Willison, and H.P. Hartung Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system Muscle Nerve 30 2004 131 156
15. C. Lambert, A.M. Landau, and J. Desbarats Fas-beyond death: a regenerative role for Fas in the nervous system Apoptosis 8 2003 551 562
16. Y.H. Lee, Y.R. Kim, J.D. Ji, J. Sohn, and G.G. Song Fas promoter -670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus J. Rheumatol. 28 2001 2008 2011
17. M. Li-Weber, and P.H. Krammer Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system Semin. Immunol. 15 2003 145 157
18. C.G. Mullighan, S. Heatley, S. Lester, M. Rischmueller, T.P. Gordon, and P.G. Bardy Fas gene promoter polymorphisms in primary Sjogren's syndrome Ann. Rheum. Dis. 63 2004 98 101
19. I. Nachamkin Campylobacter enteritis and the Guillain-Barré Syndrome Curr. Infect. Dis. Rep. 3 2001 116 122
20. F. Rieux-Laucat, S. Blachere, S. Danielan, J.P. De Villartay, M. Oleastro, E. Solary, B. Bader-Meunier, P. Arkwright, C. Pondare, F. Bernaudin, H. Chapel, S. Nielsen, M. Berrah, A. Fischer, and F. Le Deist Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant expression of the clinical manifestations Blood 94 1999 2575 2582
21. F. Rieux-Laucat, A. Fischer, and F.L. Deist Cell-death signaling and human disease Curr. Opin. Immunol. 15 2003 325 331
22. K. Sibley, S. Rollinson, J.M. Allan, A.G. Smith, G.R. Law, P.L. Roddam, C.F. Skibola, M.T. Smith, and G.J. Morgan Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia Cancer Res. 63 2003 4327 4330
23. M.C. Sneller, J. Wang, J.K. Dale, W. Strober, L.A. Middelton, Y. Choi, T.A. Fleisher, M.S. Lim, E.S. Jaffe, J.M. Puck, M.J. Lenardo, and S.E. Straus Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis Blood 89 1997 1341 1348
24. M. Tanaka, T. Suda, K. Haze, N. Nakamura, K. Sato, F. Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ohga, K. Hatake, A.H. Drummond, and S. Nagata Fas ligand in human serum Nat. Med. 2 1996 317 322
25. F.G. van der Meché, and P.I. Schmitz A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group N. Engl. J. Med. 326 1992 1123 1129
26. R. van Koningsveld, P.A. van Doorn, P.I. Schmitz, C.W. Ang, and F.G. van der Meché Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands Neurology 54 2000 620 625
27. R. Van Koningsveld, P.I. Schmitz, C.W. Ang, J. Groen, A.D. Osterhaus, F.G. Van der Meché, and P.A. Van Doorn Infections and course of disease in mild forms of Guillain-Barré syndrome Neurology 58 2002 610 614
28. R. van Koningsveld, P.I. Schmitz, F.G. Meché, L.H. Visser, J. Meulstee, and P.A. van Doorn Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial Lancet 363 2004 192 196
29. G. Wohlleben, S.M. Ibrahim, J. Schmidt, K.V. Toyka, H.P. Hartung, and R. Gold Regulation of Fas and FasL expression on rat Schwann cells Glia 30 2000 373 381
30. J. Wu, C. Metz, X. Xu, R. Abe, A.W. Gibson, J.C. Edberg, J. Cooke, F. Xie, G.S. Cooper, and R.P. Kimberly A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients J. Immunol. 170 2003 132 138
31. F. Zipp, U. Wendling, M. Beyer, U. Grieger, S. Waiczies, B. Wagenknecht, J. Haas, and M. Weller Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells J. Neuroimmunol. 110 2000 214 222